Source: Fox News
Summary
A new study suggests that high-dose vitamin B3 (niacin) may enhance immune activity and improve short-term disease control in glioblastoma patients when added to standard therapy. The study, published in the Journal of Neuro-Oncology, included 24 patients with glioblastoma and found that 82% of patients showed no disease progression after six months of niacin treatment, compared to the typical 54%. The researchers also found that niacin restored function in weakened immune cells, improving their ability to target and destroy tumor cells.
Our Reading
The advice sounds familiar.
High-dose vitamin B3 is being explored as a potential addition to standard therapy for glioblastoma, with early results showing promise. The study’s lead author, Roldan Urgoiti, noted that glioblastoma is the most aggressive brain cancer in adults and that anything that may help should be explored. However, the researchers also cautioned that high doses of vitamins can pose health risks and that usage should be monitored by doctors. Dr. Marc Siegel, Fox News senior medical analyst, agreed that niacin has some side effects, including skin blushing.
The study’s small sample size and lack of a randomized control group also posed limitations, and larger, controlled trials are needed to confirm the findings.
Despite the promising early results, the researchers urged caution, and Dr. Siegel noted that there will probably be a small impact, but it’s useful information.
It’s a familiar cycle: a new study emerges, showing promise for a particular treatment or supplement, and experts urge caution while also acknowledging the potential benefits.
